Sign In  |  Register  |  About Mill Valley  |  Contact Us

Mill Valley, CA
September 01, 2020 1:29pm
7-Day Forecast | Traffic

  • Search Hotels in Mill Valley

  • CHECK-IN:
  • CHECK-OUT:
  • ROOMS:
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Prothena Corp (NQ: PRTA )

17.70 +0.21 (+1.20%)
Streaming Delayed Price Updated: 4:00 PM EST, Nov 8, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Prothena Corp

< Previous 1 2 3 4 5 6 7 Next >
Novo Nordisk To Buy Prothena's ATTR Amyloidosis Program For Up To $1.2B
Novo Nordisk A/S (NYSE: NVO) will acquire Prothena Corporation plc's (NASDAQ: PRTA) and clinical stage antibody PRX004 and broader ATTR amyloidosis... 
Via Benzinga
64 Biggest Movers From Friday
Gainers Sentage Holdings Inc. (NASDAQ: SNTG) shares surged 597.8% to settle at $34.89 on Friday as the company priced its IPO at $5 per share. SGOCO Group, Ltd. (NASDAQ: SGOC)... 
Via Benzinga
Topics Initial Public Offering
Exposures Securities Market
Earnings Scheduled For May 11, 2021
Companies Reporting Before The Bell • Oxford Lane Capital (NASDAQ:OXLC) is estimated to report earnings for its fourth quarter. • ReWalk Robotics (NASDAQ:RWLK) is... 
Via Benzinga
12 Health Care Stocks Moving In Friday's Intraday Session
Gainers Galectin Therapeutics (NASDAQ:GALT) shares moved upwards by 35.0% to $3.73 during Friday's regular session. As of 12:30 EST, Galectin Therapeutics's stock... 
Via Benzinga
40 Stocks Moving In Friday's Mid-Day Session
Gainers Stamps.com Inc. (NASDAQ: STMP) jumped 63.7% to $323.63. Software investment firm Thoma Bravo inked an agreement to acquire e-commerce shipping solutions provider Stamps.... 
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For June 18, 2021
Upgrades According to JP Morgan, the prior rating for Orion Engineered Carbons SA (NYSE: 
Via Benzinga
Return On Capital Employed Overview: Prothena Corp
In Q1, Prothena Corp (NASDAQ:PRTA) posted sales of $160.00 thousand. Earnings were up 5.94%, but Prothena Corp still reported an overall loss of $32.11 million. Prothena Corp... 
Via Benzinga
50 Biggest Movers From Yesterday
Gainers Verve Therapeutics, Inc. (NASDAQ: VERV) shares surged 68% to settle at $31.92 on Thursday after the company priced its IPO at $19 per share. Midatech Pharma plc (NASDAQ... 
Via Benzinga
Topics Initial Public Offering
Exposures Securities Market
12 Health Care Stocks Moving In Thursday's Intraday Session
Gainers Midatech Pharma (NASDAQ:MTP) stock rose 36.76% to $2.79 during Thursday's regular session. Midatech Pharma's stock is trading at a volume of 69.8 million... 
Via Benzinga
34 Stocks Moving In Thursday's Mid-Day Session
Gainers Cellect Biotechnology Ltd. (NASDAQ: APOP) shares jumped 68.5% to $5.51 after the company announced it filed a registration statement in connect with the proposed merger... 
Via Benzinga
12 Health Care Stocks Moving In Wednesday's After-Market Session
Gainers Satsuma Pharmaceuticals (NASDAQ:STSA 
Via Benzinga
Stocks That Hit 52-Week Highs On Tuesday
Before 10 a.m. ET on Tuesday, 125 stocks hit new 52-week highs. Significant Points: The largest company by market cap to set a new 52-week high was Alphabet (NASDAQ... 
Via Benzinga
Stocks That Hit 52-Week Highs On Monday
During Monday's morning session, 255 companies made new 52-week highs. Points of Interest: The largest company by market cap to set a new 52-week high was Adobe (... 
Via Benzinga
Biotechs Ready To Roar
The biggest event last week was the FDA decision to approve Biogen's drug aducanumab, a treatment for Alzheimer's disease. The decision will reverberate across the industry and the healthcare sector... 
Via Talk Markets
Exposures Product Safety
10 Biggest Price Target Changes For Friday
Barclays lowered Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) price target from $302 to $285. Vertex Pharmaceuticals shares fell 13.3% to $187.88 in pre-market trading.... 
Via Benzinga
Why Biogen, Lilly, and Prothena Stocks Soared This Week
The FDA's approval of Biogen's Aduhelm in treating Alzheimer's disease boosted all three stocks. 
Via The Motley Fool
Exposures Product Safety
10 Biggest Price Target Changes For Thursday
Telsey Advisory Group lifted RH (NYSE: RH) price target from $675 to $725. RH shares rose 8.3% to $662.00 in pre-market trading. Keybanc raised the price target on Oxford... 
Via Benzinga
66 Biggest Movers From Yesterday
Gainers Orphazyme A/S (NASDAQ: ORPH) shares jumped 302.3% to close at $21.00 on Thursday. Shares of the biopharmaceutical firm touched an intraday high of $77.77, running up 1,... 
Via Benzinga
Biogen Snagged: Will Hefty Price Tag Hinder Alzheimer's Drug Use?
Biogen stock dipped Tuesday as analysts questioned how much use its potential blockbuster Alzheimer's treatment, Aduhelm, would ultimately secure. 
Via Investor's Business Daily
60 Biggest Movers From Yesterday
Gainers Ra Medical Systems, Inc. (NYSE: RMED) shares surged 87.3% to close at $9.14 on Monday on abnormally-high session volume. EXFO Inc. (NASDAQ: EXFO) gained 60.3% to settle... 
Via Benzinga
12 Health Care Stocks Moving In Monday's Intraday Session
Gainers Atossa Therapeutics (NASDAQ:ATOS)... 
Via Benzinga
Return On Capital Employed Overview: Prothena Corp
In Q1, Prothena Corp (NASDAQ:PRTA) posted sales of $160.00 thousand. Earnings were up 5.94%, but Prothena Corp still reported an overall loss of $32.11 million. In Q4, Prothena... 
Via Benzinga
Stocks That Hit 52-Week Highs On Friday
Before 10 a.m. ET Friday, 188 stocks made new 52-week highs. Things to Consider: The largest company by market cap to set a new 52-week high was Coca-Cola (NYSE:KO... 
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For May 26, 2021
Upgrades Bernstein upgraded the previous rating for Wipro Ltd (NYSE:WIT) from Underperform to Market Perform. Wipro earned $0.07 in the fourth quarter, compared to $0.05... 
Via Benzinga
Prothena Receives $60M Milestone Payment After Parkinson's Candidate Moves Forward In Mid-Stage Study With Dosing
Prothena Corporation plc (NASDAQ: PRTA) has dosed the first patient in the Phase 2b PADOVA study evaluating prasinezumab in patients with early... 
Via Benzinga
Cognitive Assessment And Training Market Size Expected To Reach $15.65 Billion In 2028
Via FinancialNewsMedia
Exposures COVID-19
The Daily Biotech Pulse: FDA Authorizes Pfizer-BioNTech COVID-19 Vaccine For Adolescents, Lilly Strikes R&D Collaboration, Vaccine Stocks Novavax, Inovio Sink On Earnings
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs May 10) AbbVie Inc. (NYSE: ABBV) -... 
Via Benzinga
Exposures COVID-19 Product Safety
The Week Ahead In Biotech (May 9-15): Heron, Apellis FDA Decisions, Presentations and Earnings
Biotech stocks came under pressure in the week ended May 7 as traders digested a slew of earnings news flow and a handful of clinical trial readouts. COVID-19 vaccine stocks came... 
Via Benzinga
Exposures COVID-19 Product Safety
The Week Ahead In Biotech: Johnson & Johnson, Biogen Earnings, Neurology Conference And IPOs
The FDA and CDC announced their recommendation to pause the use of Johnson & Johnson's JNJ COVID-19 vaccine following incidences of severe clots. J&J's pain turned into gains for other COVID-19 vaccine... 
Via Talk Markets
Exposures COVID-19 Product Safety
The Week Ahead In Biotech: Johnson & Johnson, Biogen Earnings, Neurology Conference And IPOs
Biotech stocks reversed course in the week ended April 16, with the sector rebounding along with the broader market. The week's news flow was fairly light. The American... 
Via Benzinga
< Previous 1 2 3 4 5 6 7 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
 
 
About Us | Contact Us | Privacy Policy | User Agreement | Advertise With Us | Site Map
Copyright © 2010-2020 MillValley.com & California Media Partners, LLC. All rights reserved.